Compare · APGE vs BIIB
APGE vs BIIB
Side-by-side comparison of Apogee Therapeutics Inc. (APGE) and Biogen Inc. (BIIB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APGE and BIIB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $28.68B, about 4.6x APGE ($6.24B).
- Over the past year, APGE is up 94.7% and BIIB is up 46.0% - APGE leads by 48.6 points.
- BIIB has been more active in the news (11 items in the past 4 weeks vs 7 for APGE).
- BIIB has more recent analyst coverage (25 ratings vs 19 for APGE).
- Company
- Apogee Therapeutics Inc.
- Biogen Inc.
- Price
- $82.62-2.80%
- $194.31-2.44%
- Market cap
- $6.24B
- $28.68B
- 1M return
- -2.27%
- -1.88%
- 1Y return
- +94.67%
- +46.03%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- News (4w)
- 7
- 11
- Recent ratings
- 19
- 25
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest APGE
- Chief Medical Officer Dambkowski Carl exercised 4,125 shares at a strike of $22.86 and sold $432,905 worth of shares (5,500 units at $78.71) as part of a pre-agreed trading plan, decreasing direct ownership by 0.66% to 205,648 units (SEC Form 4)
- Apogee Therapeutics to Participate in Upcoming June Conferences
- Apogee Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure
- Apogee Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events
- Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
- Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
- Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026
- Chief Executive Officer Henderson Michael Thomas sold $1,641,711 worth of shares (20,000 units at $82.09) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,115,987 units (SEC Form 4)
- SEC Form 144 filed by Apogee Therapeutics Inc.
- SEC Form 10-Q filed by Apogee Therapeutics Inc.
Latest BIIB
- Biogen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Amendment: Biogen Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- Biogen upgraded by Needham with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.
- Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
- EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
- Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
- UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
- Stoke Therapeutics to Present at Upcoming Investor Conferences in June
- Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease